Because of the key role of NLRP3 inflammasome activation in the pathogenesis of SARS-CoVs diseases and the promising results obtained by inhibitors of the NLRP3 inflammasome in pre-clinical and/or clinical studies [197], it can be hypothesized that its inhibition may potentially decrease tissue inflammation also in COVID-19. This evidence concerns the gene NLRP3 and COVID-19.